Parecoxib in Total Knee Arthroplasty
Key facts
- Who runs it
- University of Chile
- Where
- Chile1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 40 people enrolled
- Started
- 6 Jul 2023
- Ended
- 1 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Intravenous study drug
- Intravenous saline solution
- Record updated
- 15 May 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- ASA I - III BMI 20 - 35 (kg/m2)
Who cannot take part
- Allergy to local anesthetics, morphine, paracetamol, ketorolac or parecoxib
- Chronic pain syndromes that require the use of opioids at home
- Known history of sulfa allergy
- History of ischemic heart disease
- History of chronic gastritis or peptic ulcer
- Coagulation disturbance (assessed on history and physical examination, if clinically necessary, by blood test, i.e. platelets ≤ 100,000, international normalized ratio ≥ 1.4 or prothrombin time ≥ 50)
- Renal failure (assessed by history and physical examination, if considered clinically necessary, by blood test, i.e. creatinine ≥ 1.04 mg/dl)
- Hepatic impairment (assessed by history and physical examination, if considered clinically necessary, by blood tests, i.e. transaminases (GGT ≥ 50 u/lt)
- Adults who are not capable of giving their own consent
- Pre-existing neuropathy (assessed in the history and physical examination)
- Pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Early mobilization and rehabilitation can be difficult after total knee arthroplasty (TKA) due to a high incidence of moderate to severe postoperative pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are important to multimodal analgesic protocols. Parecoxib is an NSAID that selectively inhibits the enzyme cyclooxygenase-2 (COX-2). Clinical trials have shown that it does not alter platelet function or gastric mucosa. A recent study, after comparing ketorolac and parecoxib used at the same time in infiltration and systemically, found no differences in perioperative analgesia with a tendency to less bleeding in the parecoxib group. This randomized study will compare the effectiveness of adding a COX-2 inhibitor in the pain management of patients undergoing TKA as part of a multimodal analgesia regimen. The morphine consumption was selected as the primary outcome. The study hypothesis is that patients receiving parecoxib would have a lower opioid consumption.
The 2 groups in the trial
- ParecoxibTreatment being tested
This arm will receive intravenous parecoxib in the intraoperative period.
Treatment: Intravenous study drug
- PlaceboPlacebo, for comparison
This arm will receive a placebo intravenous injection containing saline solution in the same volume as the intervention group
Treatment: Intravenous saline solution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Comparison Between Parecoxib and Placebo Added to a Standard Perioperative Analgesic Protocol for Total Knee Arthroplasty
- Record updated
- 15 May 2025